Stable Antibody-Drug Conjugate via Ligase Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges with linker stability and heterogeneity, leading to unpredictable drug release and efficacy, particularly due to the instability of sulfosuccinimide linkers which can lead to off-target toxicity and variable drug loading.
Innovation Solution
A novel linker-payload intermediate system utilizing ligase-dependent conjugation technology for site-specific coupling of cytotoxins to antibodies, enabling a stable ring-open structure that avoids harsh processing conditions and ensures homogeneous ADC production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If sulfosuccinimide linkers are used to connect cytotoxins to antibodies, then the coupling reaction is fast and quantitative under mild conditions, but the linker stability is poor leading to off-target toxicity
Solution Approach 1:
The patent changes the chemical structure parameters of the linker by introducing a novel stable linkage structure (such as tetrahydrothiophene-3-carboxylic acid derivatives) that maintains coupling efficiency while improving in vivo stability. This structural parameter change resolves the contradiction between ease of manufacture and reliability.
2Ease of manufacture
If conventional coupling strategies are used, then the ADC preparation process is simple, but the ADC heterogeneity is high affecting quality and stability
Solution Approach 1:
The patent segments the coupling process into controlled steps with specific recognition sequences (such as LPXTG for Sortase A) that enable site-specific conjugation. This segmentation allows precise control over attachment sites, reducing heterogeneity while maintaining process feasibility.
Solution Approach 2:
The patent replaces non-specific chemical coupling mechanisms with enzyme-catalyzed conjugation (such as Sortase A or B) that provides site-specific attachment. This substitution of the coupling mechanism significantly improves ADC homogeneity and quality control.
3Reliability
If the linker structure is modified to improve stability, then the off-target toxicity is reduced, but the coupling reaction conditions become more complex
Solution Approach 1:
The patent introduces stable intermediate linkers (such as tetrahydrothiophene-3-carboxylic acid derivatives) that serve as mediators between the antibody and cytotoxin. These intermediaries provide stable in vivo performance while maintaining favorable coupling characteristics, resolving the contradiction between stability and process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances the stability and homogeneity of ADCs, reducing off-target toxicity and improving the accuracy of drug delivery, thereby increasing efficacy and safety.
Implementation Method 1
utilizing ligase-dependent conjugation technology for site-specific coupling of cytotoxins to antibodies
Implementation Method 2
the conjugation reaction between the linker-payload intermediate and the antibody is catalyzed by a ligase
Implementation Method 3
the succinimide ring-open reaction is carried out during the preparation of the linker-payload intermediate
Data Source
AI summary
The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.